June 14, 2026European Respiratory Journal
Sotatercept Blunts Ventilatory Drive to Carbon Dioxide with Improved Exertional Dyspnea in Pulmonary Arterial Hypertension
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates improved exertional dyspnea in pulmonary arterial hypertension, indicating potential therapeutic benefits of sotatercept.
Key Points
- To evaluate the effects of sotatercept on ventilatory response in patients with pulmonary arterial hypertension.
- Secondary analysis of data from a randomized trial
- Patients experienced ventilatory inefficiency and increased drive to carbon dioxide
- Assessment of exercise tolerance and ventilatory efficiency
- Sotatercept improved exercise tolerance through central, hematologic, and peripheral mechanisms
- Blunted the elevated ventilatory drive to carbon dioxide observed in patients
- No increase in cardiac output was noted, unlike vasodilator treatments
Cite This Study
Reddy et al. (2026) studied this question.